Prozkoumejte nejčtenější články a videa na Campus Sanofi
This video explores the long-term, multi-dimensional burden of moderate-to-severe atopic dermatitis, highlighting its impact beyond the skin. It emphasizes the importance of early intervention targeting type 2 inflammation to alter the disease course and prevent long-term comorbidities.
Discover the science beyond histamine: This video reveals how chronic itch in atopic dermatitis is predominantly mediated through non-histaminergic pathways. Learn how IL-4 and IL-13, key drivers of type 2 inflammation, create a critical intersection between inflammatory cascades and neural itch signaling. Understand the clinical implications of targeting these dual cytokines to simultaneously address both inflammation and the persistent itch cycle that significantly impacts patient quality of life.
This video provides insights into the key components and functions of the epithelial barriers in the skin. It highlights how barrier dysfunction plays a central role in the pathology of atopic dermatitis and emphasizes the importance of transepidermal water loss as a marker of barrier integrity and disease severity.
This video highlights prurigo nodularis (PN) as a systemic disorder driven by neural inflammation and immune dysregulation. Key inflammatory mediators IL-4 and IL-13, along with fibrosis, emerge as central features, emphasizing the need for targeted therapies that address both neural and immune pathways.
Delay in screening for autoimmune type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.1,2 By identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.3,4